Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Girmenia, C. Articles by Martino, P. Search for Related Content PubMed PubMed Citation Articles by Girmenia, C. Articles by Martino, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2003, p. 3985-3988, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3985-3988.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibility Testing of Geotrichum capitatum: Comparison of the E-Test, Disk Diffusion, and Sensititre Colorimetric Methods with the NCCLS M27-A2 Broth Microdilution Reference Method

C. Girmenia,^1* G. Pizzarelli,² D. D'Antonio,³ F. Cristini,⁴ and P. Martino¹

Dipartimento di Biotecnologie Cellulari ed Ematologia, Università "La Sapienza,",¹ Pfizer Italia SpA, Rome,² Servizio di Microbiologia Clinica del Dipartimento di Ematologia ed Oncologia, Ospedale Spirito Santo, Pescara,³ Clinica di Malattie Infettive, Dipartimento di Scienze Mediche e Morfologiche, Università di Udine, Udine, Italy⁴

Received 5 August 2003/ Returned for modification 13 August 2003/ Accepted 8 September 2003

Top Abstract Text References

 
The in vitro activities of amphotericin B, flucytosine, fluconazole, itraconazole, and voriconazole against 23 isolates of Geotrichum capitatum were determined by the National Committee for Clinical Laboratory Standards (NCCLS) M27-A2 microdilution method and the Sensititre and agar diffusion methods. Amphotericin B and voriconazole appeared to be the more active drugs. Sensititre showed the highest rates of agreement with the NCCLS M27-A2 method.

Top Abstract Text References

 
Geotrichum capitatum, formerly known as Trichosporon capitatum or Blastoschizomyces capitatus, is an uncommon but frequently fatal cause of invasive infections in immunocompromised patients, particularly those with hematological malignancies (1, 3, 5, 6). Data on its antifungal agent susceptibilities are limited (3, 4, 5, 14); however, fluconazole-resistant strains have been reported (3, 4). The National Committee for Clinical Laboratory Standards (NCCLS) provides no specific guidelines for in vitro antifungal susceptibility testing for this fungus. Other susceptibility methods also have not been validated for use with G. capitatum. In this study, we evaluated the in vitro activities of five antifungal agents, including voriconazole, against clinical isolates of G. capitatum, using the standard broth microdilution NCCLS M27-A2 method (9) and alternative methods.

The study was conducted on 23 clinical isolates of G. capitatum collected from blood (n = 17), lower respiratory tract (n = 2), upper respiratory tract (n = 2), and urinary tract (n = 2) specimens. Quality control strains of Candida albicans (ATCC 90028) and Candida parapsilosis (ATCC 22019) were included in every test run. In vitro susceptibilities to amphotericin B, flucytosine, itraconazole, fluconazole, and voriconazole were determined by the NCCLS M27-A2 broth microdilution method (9), Sensititre YeastOne colorimetric method (AccuMedInternational) (8), and E-test method (12). Susceptibilities to fluconazole and voriconazole were also evaluated by the NCCLS M44-P disk diffusion method (7, 10, 12). Both agar diffusion methods were used with three different agars: RPMI 1640 with 2% glucose and 1.5% Bacto Agar (Difco Laboratories; RPMI-2%), Mueller-Hinton agar (Difco Laboratories) supplemented with 2% glucose and methylene blue (0.5 µg/ml; MHB), and Antibiotic Medium 3 with 2% glucose and 1.5% Bacto Agar (Difco Laboratories; AM3-2%). MIC endpoints were determined after 24 (Sensititre and disk diffusion) or 48 (NCCLS and E-test methods) h of incubation at 35°C. For disk diffusion results, the diameter of each zone of inhibition was taken as the area that showed a sharp decline (80%) in the density of growth (2). To facilitate reading more consistent and objective endpoints, the BIOMIC image analysis plate reader system (Giles Scientific, Santa Barbara, Calif.) was used (12), and these values were automatically converted into MICs by the BIOMIC System regression analysis software, which is calibrated against the NCCLS reference method MICs. Ranges for MICs and for MICs at which 50 and 90% of the isolates tested were inhibited were calculated for each of the methods used. For each testing method, the rate of agreement (within ±2 log₂ dilutions) with the NCCLS reference method was calculated. MICs determined by the E-test and disk diffusion methods that fell between the twofold dilutions of the MICs of the NCCLS method were elevated to the next drug concentration so that they matched the twofold dilution scheme. Isolates were classified as susceptible (S), susceptible-dose-dependent (S-DD) orintermediate (I), or resistant (R) to fluconazole, itraconazole, and flucytosine based on the criteria of Rex et al. (13) and those of the NCCLS (9). NCCLS-validated breakpoints have not yet been established for amphotericin B or voriconazole, but for the purposes of this study, we adapted the arbitrarily chosen criteria for these drugs proposed by Pfaller et al. (11, 12), who considered MICs of 1 µg/ml (for both drugs) indicative of susceptibility.

The interpretive classifications of the isolates yielded by each test method were compared to those obtained with the NCCLS reference method, and discrepancies were defined as follows: (i) minor, isolate classified as S or R by one test (reference method or alternative method) and as S-DD or I by the other method; (ii) major, isolate classified as S by the reference method and R by the other method; and (iii) very major, isolate classified as R by the reference method and S by the other method.

The MICs for the two quality control Candida strains yielded by the various methods were all within the reference ranges, with the exception of those that emerged for flucytosine in E-tests with MHB agar, both of which were high (>32 µg/ml).

In G. capitatum susceptibility testing with the NCCLS M27-A2 method, fungal growth was clearly visible after 24 h of incubation and somewhat more evident by 48 h, but the 24- and 48-h MICs never differed by more than one dilution. Trailing growth, which did not occur with amphotericin B, was observed with most strains in the presence of fluconazole and itraconazole and occasionally with flucytosine and voriconazole. Nonetheless, interpretation of MICs was not difficult.

Tables 1 and 2 summarize the antifungal susceptibility profiles of the 23 G. capitatum isolates. A review of reference method data in these two tables shows that all G. capitatum isolates were susceptible to both amphotericin B and voriconazole, and 90% were inhibited by very low concentrations of the drugs (0.125 and 0.25 µg/ml, respectively). For these two drugs, the other methods showed good concordance with the reference method. The only exception was the disk diffusion method on MHB agar for voriconazole.

View this table: [in this window] [in a new window]

TABLE 1. In vitro susceptibilities of 23 isolates of G. capitatum to five antifungal agents as determined by different methods

View this table: [in this window] [in a new window]

TABLE 2. Interpretive antifungal susceptibility classification of 23 isolates of G. capitatum determined by different methods

The reference method MICs of flucytosine, itraconazole, and fluconazole tended to be clustered within the upper limits of the S category and in the S-DD and/or I category. Sensititre results showed the highest rates of agreement with those of the NCCLS M27-A2 method. Regardless of the agar used, E-test results for these three drugs showed lower concordance with the reference method data. The poorest results were seen when flucytosine was subjected to the E-test on MHB agar. When discrepancies were observed between E-test and reference method results for these three drugs, the MICs indicated by the E-test were generally higher. Disk diffusion test results for fluconazole showed good concordance with the reference method data, with the exception of the test on MHB agar, which showed very low rates of isolate categorical agreement (43.5%).

As shown in Table 2, none of the interpretive classifications yielded by the alternative methods represented "very major" discrepancies with respect to the NCCLS reference method. Concordance was particularly high for data for amphotericin B (100% agreement) and voriconazole. For the latter drug, disk diffusion testing on MHB agar was the only method that yielded discordant data (major discrepancies for 43.5% of all strains tested).

In summary, this extensive analysis of methods currently available for determination of the in vitro activities of amphotericin B, flucytosine, itraconazole, fluconazole, and voriconazole provides antifungal susceptibility data for the largest series of G. capitatum isolates tested thus far in a single setting. We did not encounter difficulties in the interpretation of the NCCLS M27-A2 method results. As alternatives to this method, the Sensititre Yeast One method proved to be the most "reliable" for evaluation of all five antifungal agents, although acceptable results were also obtained with E-tests on RPMI-2% or AM3-2% agar. For fluconazole and voriconazole susceptibility testing, reliable results were obtained with all three of the E-test methods and with disk diffusion testing (except that performed on MHB agar). Our findings tend to confirm previous observations on the high activity of amphotericin B against G. capitatum (6, 14) and the reduced susceptibility of some strains to flucytosine, fluconazole, and itraconazole (3). They also provide encouraging evidence of the potential role of voriconazole in our therapeutic armamentarium against invasive G. capitatum infections.

 
This work was supported by a grant from Pfizer Italia.

 
* Corresponding author. Mailing address: Dipartimento di Biotecnologie Cellulari ed Ematologia Università "La Sapienza," Via Benevento 6, 00161 Rome, Italy. Phone: 39-06-857951. Fax: 39-06-85795555. E-mail: girmenia{at}bce.uniroma1.it.

Top Abstract Text References

 

1
1. Anaissie, E., A. Gokaslan, R. Hachem, R. Rubin, G. Griffin, R. Robinson, J. Sobel, and G. Bodey. 1992. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin. Infect. Dis. 15:781-787.[Medline]
2
2. Barry, A. L., M. A. Pfaller, R. P. Renne, P. C. Fuchs, and S. D. Brown.2002 . Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods.Antimicrob. Agents Chemother. 46:1781-1784.[Abstract/Free Full Text]
3
3. D'Antonio, D., A. Mazzoni, A. Icone, B. Violante, M. A. Capuani, F. Schioppa, and F. Romano. 1996. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J. Clin. Microbiol. 34:753-755.[Abstract/Free Full Text]
4
4. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.J. Clin. Microbiol. 36:198-202.[Abstract/Free Full Text]
5
5. Girmenia, C., A. Micozzi, M. Venditti, G. Meloni, A. P. Iori, S. Bastianello, and P. Martino. 1991. Fluconazole treatment of Blastoschizomyces capitatus meningitis in an allogeneic bone marrow recipient. Eur. J. Clin. Microbiol. Infect. Dis. 10:752-756.[CrossRef][Medline]
6
6. Martino, P., M. Venditti, A. Micozzi, G. Morace, L. Polonelli, M. P. Mantovani, M. C. Petti, V. L. Burgio, C. Santini, P. Serra, and F. Mandelli. 1990. Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev. Infect. Dis. 12:570-582.[Medline]
7
7. Matar, M. J., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex.2003 . Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 47:1647-1651.[Abstract/Free Full Text]
8
8. Morace, G., G. Amato, F. Bistoni, G. Fadda, P. Marone, M. T. Montagna, S. Olivieri, L. Polonelli, R. Rigoli, I. Mancuso, S. La Face, L. Masucci, L. Romano, C. Napoli, D. Tatò, M G. Buscema, C. M. C. Belli, M. M. Piccirillo, S. Conti, S. Covan, F. Fanti, C. Capanna, F. D'Alò, and L. Pitzurra. 2002. Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J. Clin. Microbiol. 40:2953-2958.[Abstract/Free Full Text]
9
9. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10
10. National Committee for Clinical Laboratory Standards. 2003. Method for antifungal disk diffusion susceptibility testing of yeasts: proposed guideline M44-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11
11. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema.2002 . In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.[Abstract/Free Full Text]
12
12. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis. 2003. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility program, 2001. J. Clin. Microbiol. 41:1440-1446.[Abstract/Free Full Text]
13
13. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of the interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.[Medline]
14
14. Venditti, M., B. Posteraro, G. Morace, and P. Martino. 1991. In-vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus.J. Chemother. 3:13-15.[Medline]

---

Antimicrobial Agents and Chemotherapy, December 2003, p. 3985-3988, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3985-3988.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Girmenia, C., Pagano, L., Martino, B., D'Antonio, D., Fanci, R., Specchia, G., Melillo, L., Buelli, M., Pizzarelli, G., Venditti, M., Martino, P., the GIMEMA Infection Program, (2005). Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature. J. Clin. Microbiol. 43: 1818-1828 [Abstract] [Full Text]  
• Pfaller, M. A., Diekema, D. J. (2004). Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42: 4419-4431 [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Girmenia, C. Articles by Martino, P. Search for Related Content PubMed PubMed Citation Articles by Girmenia, C. Articles by Martino, P.